0 TSX News - December 8, 2024Aura Minerals Announces Positive Exploration Results from Multiple High-Potential ProjectsROAD TOWN, British Virgin Islands, Dec. 08, 2024 (GLOBE NEWSWIRE) — Aura Minerals Inc. (TSX: ORA) (B3: AURA33) (OTCQX: ORAAF) […]Read More
0 NASDAQ Companies - December 8, 2024Lead Real Estate Co., Ltd. Opening New Apartment Hotel, ENT TERRACE GINZA PREMIUM, in TokyoTOKYO, Dec. 08, 2024 (GLOBE NEWSWIRE) — Lead Real Estate Co., Ltd. (Nasdaq: LRE) (“LRE” or “the Company”), a Japanese […]Read More
0 NASDAQ Companies - December 8, 2024Australia’s Rangebank Battery Energy Storage System, Victoria’s second largest battery, is openedMELBOURNE, Australia, Dec. 08, 2024 (GLOBE NEWSWIRE) — Fluence Energy, Inc. (“Fluence” or the “Company”) (NASDAQ: FLNC), a global market […]Read More
0 NASDAQ Companies - December 8, 2024Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual MeetingDemonstrated durable hematologic response across all patient subgroups, regardless of baseline transfusion status and concomitant JAK inhibitor therapy Phase 2 […]Read More
0 NASDAQ Companies - December 8, 2024Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual MeetingNHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust […]Read More
0 NASDAQ Companies - December 8, 2024Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat– ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia – – […]Read More
0 NASDAQ Companies - December 8, 2024Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024MP0533 phase 1/2a dose escalation study continues with overall acceptable safety profile to date as well as initial antileukemic and […]Read More
0 TSX Venture News - December 8, 2024CWTI Provides Revised Update on Canada Postal Strike Delay Mailing of the Company’s 2024 Annual General Meeting MaterialsGUELPH, Ontario, Dec. 08, 2024 (GLOBE NEWSWIRE) — Current Water Technologies Inc. (TSX-V: WATR) (“CWTI” or “the Company” or “the Corporation“), […]Read More